Edition:
United Kingdom

Tetraphase Pharmaceuticals Inc (TTPH.OQ)

TTPH.OQ on NASDAQ Stock Exchange Global Select Market

6.24USD
17 Jan 2018
Change (% chg)

-- (--)
Prev Close
$6.24
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
185,742
52-wk High
$9.69
52-wk Low
$3.59

Chart for

About

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral... (more)

Overall

Beta: 2.59
Market Cap(Mil.): $396.17
Shares Outstanding(Mil.): 51.05
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.44
EPS (TTM): -- -- --
ROI: -- 14.85 10.61
ROE: -- 16.31 14.21

BRIEF-Tetraphase Pharmaceuticals Announces Submission Of NDA To FDA For Eravacycline To Treat Intra-Abdominal Infections

* TETRAPHASE PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO FDA FOR ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)

02 Jan 2018

BRIEF-Millennium Management Llc Reports 5.3 Pct Passive Stake In Tetraphase Pharmaceuticals As On Dec 14

* MILLENNIUM MANAGEMENT LLC REPORTS 5.3 PERCENT PASSIVE STAKE IN TETRAPHASE PHARMACEUTICALS AS ON DEC 14 - SEC FILING Source text: (http://bit.ly/2kt52WQ) Further company coverage:

20 Dec 2017

BRIEF-Tetraphase Pharmaceuticals Q3 loss per share $0.63

* Tetraphase pharmaceuticals reports third quarter 2017 financial results and highlights recent clinical and corporate achievements

02 Nov 2017

BRIEF-Tetraphase Pharmaceuticals signs commercial supply agreement with Finorga

* Tetraphase Pharmaceuticals Inc says ‍on October 16 co and finorga sas entered into a commercial supply agreement​ - sec filing

20 Oct 2017

BRIEF-TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CFO

* TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CHIEF FINANCIAL OFFICER

16 Oct 2017

BRIEF-Tetraphase Pharmaceuticals presents clinical data from oral eravacycline development program at IDWEEK 2017​

* Tetraphase Pharmaceuticals - ‍phase 2 trial in patients with complicated urinary tract infections expected to begin in h1 2018​

04 Oct 2017

BRIEF-Tetraphase Pharmaceuticals completes enrollment of ignite3 phase 3 clinical trial of eravacycline

* Tetraphase Pharmaceuticals completes enrollment of ignite3 phase 3 clinical trial of eravacycline in complicated urinary tract infections

11 Sep 2017

BRIEF-Tetraphase announces validation of IV eravacycline MAA by European Medicines Agency

* Tetraphase Pharmaceuticals announces submission and validation of IV eravacycline marketing authorization application by European Medicines Agency

17 Aug 2017

BRIEF-Tetraphase announces pricing of public offering of common stock

* Tetraphase announces pricing of public offering of common stock

28 Jul 2017

BRIEF-Tetraphase announces proposed public offering of common stock

* Tetraphase announces proposed public offering of common stock

26 Jul 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $146.98 +0.12
Pfizer Inc. (PFE.N) $37.18 +0.58
Merck & Co., Inc. (MRK.N) $62.03 -0.04
AstraZeneca plc (AZN.L) 4,950.00 -40.50

Earnings vs. Estimates